{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:31:40Z","timestamp":1780965100407,"version":"3.54.1"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110542","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T02:34:50Z","timestamp":1748831690000},"page":"110542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Unlocking molecular secrets: The role of miRNAs in Parkinson's disease dynamics"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0667-7253","authenticated-orcid":false,"given":"Rehab A.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abobakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hussieny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"tarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-8913","authenticated-orcid":false,"given":"Shereen Saeid","family":"Elshaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.14802\/jmd.19080","article-title":"Long-term outcomes of genetic Parkinson's disease","volume":"13","author":"Aasly","year":"2020","journal-title":"J. Movement Disord."},{"key":"10.1016\/j.neuropharm.2025.110542_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mgene.2018.02.007","article-title":"Association of MicroRNA related single nucleotide polymorphisms 196A-2 and 499 with the risk of hepatocellular carcinoma in Egyptian patients","volume":"16","author":"Abdel-Hamid","year":"2018","journal-title":"Meta Gene"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s12105-022-01475-0","article-title":"Prognostic impact of MUC1 and potential regulatory miR-145 and miR-21 expression in salivary mucoepidermoid carcinoma","volume":"16","author":"Abdolrahmani","year":"2022","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154584","article-title":"The potential role of miRNAs in the pathogenesis of salivary gland cancer-A Focus on signaling pathways interplay","author":"Abulsoud","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110542_bib5","doi-asserted-by":"crossref","first-page":"R762","DOI":"10.1016\/j.cub.2014.06.043","article-title":"Aberrant regulation and function of microRNAs in cancer","volume":"24","author":"Adams","year":"2014","journal-title":"Curr. Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40572-022-00380-6","article-title":"Sex differences in dopaminergic vulnerability to environmental toxicants\u2014implications for Parkinson's disease","volume":"9","author":"Adamson","year":"2022","journal-title":"Curr. Environ. Health Rep."},{"issue":"6116","key":"10.1016\/j.neuropharm.2025.110542_bib7","first-page":"156","article-title":"Microglia: scapegoat, saboteur, or something else?","volume":"339","author":"Aguzzi","year":"2013","journal-title":"Sci. Technol. Humanit."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/genes14030600","article-title":"PARK2 microdeletion or duplications have been implicated in different neurological disorders including early onset Parkinson disease","volume":"14","author":"Ahmad","year":"2023","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1074\/jbc.M102981200","article-title":"Tubulin seeds alpha-synuclein fibril formation","volume":"277","author":"Alim","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib10","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/humu.21582","article-title":"Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress\u2010induced neuronal death","volume":"32","author":"Angeles","year":"2011","journal-title":"Hum. Mutat."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110542_bib11","article-title":"Utilizing multifaceted approaches to target drug delivery in the brain: from nanoparticles to biological therapies","volume":"16","author":"Anwarkhan","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib14","article-title":"Mutation analysis of exon 3 and 4 of \u03b1-synuclein gene in Parkinson's disease patients from West Libya","volume":"25","author":"Awayn","year":"2022","journal-title":"Libyan J. Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1228927","article-title":"Common microRNA regulated pathways in Alzheimer's and Parkinson's disease","volume":"17","author":"Awuson-David","year":"2023","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110542_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbadis.2008.11.007","article-title":"Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis","volume":"1792","author":"Banerjee","year":"2009","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","article-title":"Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A\/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging","volume":"36","author":"Bar-Am","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110542_bib18","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/emm.2015.54","article-title":"Transcriptional mutagenesis by 8-oxodG in \u03b1-synuclein aggregation and the pathogenesis of Parkinson's disease","volume":"47","author":"Basu","year":"2015","journal-title":"Exp. Mol. Med."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110542_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012211","article-title":"A comprehensive assessment of qualitative and quantitative prodromal parkinsonian features in carriers of gaucher disease\u2014identifying those at the greatest risk","volume":"23","author":"Becker-Cohen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110542_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nrl.2014.10.010","article-title":"Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups","volume":"31","author":"Berganzo","year":"2016","journal-title":"Neurologia"},{"key":"10.1016\/j.neuropharm.2025.110542_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopha.2015.07.025","article-title":"Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight","volume":"74","author":"Bhat","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41419-021-03441-0","article-title":"Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown","volume":"12","author":"Bi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2025.110542_bib23","article-title":"Analysis of the functional effects mediated by dopamine oxidation products at the mitochondrial level","volume":"111 RIVER ST","author":"Biosa","year":"2017"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamaneurol.2018.1885","article-title":"Frequency of loss of function variants in LRRK2 in Parkinson disease","volume":"75","author":"Blauwendraat","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.parkreldis.2020.11.023","article-title":"Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: an update","volume":"82","author":"Borellini","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2025.110542_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.freeradbiomed.2022.12.086","article-title":"ACSL4 and the lipoxygenases 15\/15B are pivotal for ferroptosis induced by iron and PUFA dyshomeostasis in dopaminergic neurons","volume":"195","author":"Bouchaoui","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(99)00208-6","article-title":"Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by \u03b1-synuclein immunocytochemistry","volume":"265","author":"Braak","year":"1999","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151841","article-title":"Association between Parkinson's disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis","volume":"11","author":"Breckenridge","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0891-5849(00)00317-8","article-title":"Mitochondrial free radical generation, oxidative stress, and aging11This article is dedicated to the memory of our dear friend, colleague, and mentor Lars Ernster (1920\u20131998), in gratitude for all he gave to us","volume":"29","author":"Cadenas","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2025.110542_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.695007","article-title":"Aberrant expression of circulating MicroRNA leads to the dysregulation of alpha-synuclein and other pathogenic genes in Parkinson's disease","volume":"9","author":"Cai","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib31","series-title":"MicroRNA","first-page":"109","article-title":"MicroRNA turnover and nuclear function","author":"Campos-Melo","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110542_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neurobiolaging.2017.09.010","article-title":"Parkin absence accelerates microtubule aging in dopaminergic neurons","volume":"61","author":"Cartelli","year":"2018","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110542_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/1389202914666131210195808","article-title":"Genetic insights into sporadic Parkinson's disease pathogenesis","volume":"14","author":"Chai","year":"2013","journal-title":"Curr. Genom."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib34","first-page":"38","article-title":"Mitochondrial dysfunction in Parkinson's disease\u2014cause or consequence?","volume":"8","author":"Chen","year":"2019","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.neuropharm.2025.110542_bib35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbi.2020.03.022","article-title":"5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease","volume":"88","author":"Chen","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/hmg\/dds470","article-title":"MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein","volume":"22","author":"Cho","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1388655","article-title":"Integrative analysis of plasma and substantia nigra in Parkinson's disease: unraveling biomarkers and insights from the lncRNA\u2013miRNA\u2013mRNA ceRNA network","volume":"16","author":"Chun","year":"2024","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/mds.27935","article-title":"Salivary microR\u2010153 and microR\u2010223 levels as potential diagnostic biomarkers of idiopathic Parkinson's disease","volume":"35","author":"Cressatti","year":"2020","journal-title":"Mov. Disord."},{"issue":"342","key":"10.1016\/j.neuropharm.2025.110542_bib40","doi-asserted-by":"crossref","first-page":"342ra78","DOI":"10.1126\/scitranslmed.aaf3634","article-title":"\u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease","volume":"8","author":"Di Maio","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010355","article-title":"miR-218 inhibits mitochondrial clearance by targeting PRKN E3 ubiquitin ligase","volume":"21","author":"Di Rita","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110542_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154053","article-title":"A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: a focus on signaling pathways interplay","author":"Doghish","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib44","article-title":"miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance\u2013an emphasis on the interaction of signaling pathways","author":"Doghish","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154665","article-title":"miRNAs orchestration of adrenocortical carcinoma - particular emphasis on diagnosis, progression and drug resistance","volume":"248","author":"El-Dakroury","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ijbiomac.2022.06.134","article-title":"miRNAs as cornerstones in colorectal cancer pathogenesis and resistance to therapy: a spotlight on signaling pathways interplay\u2014a review","volume":"214","author":"Elrebehy","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib48","article-title":"MiR-216a in diabetic nephropathy: relation with autophagy and apoptosis","volume":"7","author":"Elshaer","year":"2018","journal-title":"Int. J. Pharmaceut. Res. Allied Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154511","article-title":"miRNAs role in glioblastoma pathogenesis and targeted therapy: signaling pathways interplay","author":"Elshaer","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014228","article-title":"Compound heterozygous mutations in PARK2 causing early-onset Parkinson disease: a case report","volume":"98","author":"Fang","year":"2019","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and \u03b1\u2010synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann. Neurol.: Offi. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib52","article-title":"CSF microRNAs reveal impairment of angiogenesis and autophagy in Parkinson disease","volume":"7","author":"Fowler","year":"2021","journal-title":"Neurology: Genetics (Austin, Tex.)"},{"key":"10.1016\/j.neuropharm.2025.110542_bib53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ceb.2020.08.015","article-title":"The multifaceted roles of microRNAs in differentiation","volume":"67","author":"Galagali","year":"2020","journal-title":"Curr. Opin. Cell Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/psyg.13109","article-title":"Regulatory mechanism of miR\u201020a\u20105p in neuronal damage and inflammation in lipopolysaccharide\u2010induced BV2 cells and MPTP\u2010HCl\u2010induced Parkinson's disease mice","volume":"24","author":"Gao","year":"2024","journal-title":"Psychogeriatrics"},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110542_bib55","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1111\/febs.14393","article-title":"The role of glucocerebrosidase in Parkinson disease pathogenesis","volume":"285","author":"Gegg","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2025.110542_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137437","article-title":"Mesenchymal stem cell exosomes rich in miR-23b-3p affect the Wnt signaling pathway and promote neuronal autophagy to alleviate PD symptoms","volume":"814","author":"Geng","year":"2023","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110542_bib57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.it.2020.07.007","article-title":"The role of astrocytes in CNS inflammation","volume":"41","author":"Giovannoni","year":"2020","journal-title":"Trends Immunol."},{"issue":"s1","key":"10.1016\/j.neuropharm.2025.110542_bib58","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"22","key":"10.1016\/j.neuropharm.2025.110542_bib59","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.3390\/ijms20225649","article-title":"Role of MicroRNAs in Parkinson's disease","volume":"20","author":"Goh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/life11050371","article-title":"PINK1: a bridge between mitochondria and Parkinson's disease","volume":"11","author":"Gon\u00e7alves","year":"2021","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110542_bib61","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1039\/C7MT00039A","article-title":"Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease\u2020","volume":"9","author":"Gotsbacher","year":"2017","journal-title":"Metallomics"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib62","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/ijms24032044","article-title":"GBA1 gene mutations in \u03b1-Synucleinopathies\u2014molecular mechanisms underlying pathology and their clinical significance","volume":"24","author":"Granek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib63","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1038\/s41598-024-57330-5","article-title":"Non-canonical RNA substrates of Drosha lack many of the conserved features found in primary microRNA stem-loops","volume":"14","author":"Gu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110542_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.648588","article-title":"Genotype-phenotype correlations in monogenic Parkinson disease: a review on clinical and molecular findings","volume":"12","author":"Guadagnolo","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43096-9","article-title":"MicroRNAs in Parkinson's disease: a systematic review and diagnostic accuracy meta-analysis","volume":"13","author":"Gu\u00e9vremont","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110542_bib66","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s12276-024-01202-5","article-title":"Experimental capture of miRNA targetomes: disease-specific 3\u2032UTR library-based miRNA targetomics for Parkinson's disease","volume":"56","author":"Hart","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0301-0082(98)00041-0","article-title":"Involvement of basal ganglia transmitter systems in movement initiation","volume":"56","author":"Hauber","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154510","article-title":"The role of miRNAs in laryngeal cancer pathogenesis and therapeutic resistance-A focus on signaling pathways interplay","author":"Hegazy","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12883-018-1187-0","article-title":"Is traumatic brain injury a risk factor for neurodegeneration? A meta-analysis of population-based studies","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib70","article-title":"Single-cell transcriptomics uncovers cellular heterogeneity, mechanisms, and therapeutic targets for Parkinson's disease","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154222","article-title":"The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance-a focus on signaling pathways interplay","author":"Ismail","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib72","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/biom13050845","article-title":"Overview of the impact of pathogenic LRRK2 mutations in Parkinson's disease","volume":"13","author":"Ito","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/toxsci\/kfaa066","article-title":"Coordinated action of miR-146a and parkin gene regulate rotenone-induced neurodegeneration","volume":"176","author":"Jauhari","year":"2020","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib75","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/cells9122565","article-title":"Pathological functions of LRRK2 in Parkinson's disease","volume":"9","author":"Jeong","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00604-018-3199-2","article-title":"Multifunctional DNA nanocage with CdTe quantum dots for fluorescence detection of human 8-oxoG DNA glycosylase 1 and doxorubicin delivery to cancer cells","volume":"186","author":"Jie","year":"2019","journal-title":"Microchim. Acta"},{"key":"10.1016\/j.neuropharm.2025.110542_bib77","series-title":"Loss of Redoxin Proteins Exacerbates LRRK2\u2010mediated Parkinson's Disease Phenotype in C. elegans","author":"Johnson","year":"2013"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human \u03b1-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jnr.21831","article-title":"Mitochondrial localization of DJ\u20101 leads to enhanced neuroprotection","volume":"87","author":"Junn","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2025.110542_bib80","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.freeradbiomed.2015.09.010","article-title":"MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression","volume":"89","author":"Kabaria","year":"2015","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.arr.2004.01.003","article-title":"Does cellular iron dysregulation play a causative role in Parkinson's disease?","volume":"3","author":"Kaur","year":"2004","journal-title":"Ageing Res. Rev."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib82","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ana.26905","article-title":"Towards a global view of Parkinson's disease genetics","volume":"95","author":"Khani","year":"2024","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13024-016-0121-4","article-title":"miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1)","volume":"11","author":"Kim","year":"2016","journal-title":"Mol. Neurodegener."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib84","doi-asserted-by":"crossref","first-page":"eadf0597","DOI":"10.1126\/sciadv.adf0597","article-title":"The Integrator complex regulates microRNA abundance through RISC loading","volume":"9","author":"Kirstein","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41531-024-00676-4","article-title":"Resequencing the complete SNCA locus in Indian patients with Parkinson's disease","volume":"10","author":"Kishore","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib86","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson's disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2025.110542_bib87","series-title":"Biologic Effect of a PINK1 Mutation: mRNA Levels of the C. 1366C> T (Gln456Stop) Change","author":"Klein","year":"2023"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib88","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/genes14112097","article-title":"The landscape of monogenic Parkinson's disease in populations of non-European ancestry: a narrative review","volume":"14","author":"Koros","year":"2023","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib89","article-title":"Artificial miRNAs as therapeutic tools: challenges and opportunities","volume":"12","author":"Kotowska\u2010Zimmer","year":"2021","journal-title":"Wiley Interdisc. Rev.: RNA"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110542_bib90","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/WNL.56.10.1355","article-title":"Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers","volume":"56","author":"Kruger","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2025.110542_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.parkreldis.2021.02.001","article-title":"Compound heterozygous variants in Wiskott-Aldrich syndrome like (WASL) gene segregating in a family with early onset Parkinson's disease","volume":"84","author":"Kumar","year":"2021","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31083\/j.fbl2901004","article-title":"Parkinson's disease diagnosis using miRNA biomarkers and deep learning","volume":"29","author":"Kumar","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31083\/j.fbl2901004","article-title":"Parkinson's disease diagnosis using miRNA biomarkers and deep learning","volume":"29","author":"Kumar","year":"2024","journal-title":"Front. Biosci. Landmark"},{"key":"10.1016\/j.neuropharm.2025.110542_bib94","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12272-019-01133-0","article-title":"Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention","volume":"42","author":"Lee","year":"2019","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/jnc.15524","article-title":"Glucocerebrosidase 1 and leucine\u2010rich repeat kinase 2 in Parkinson disease and interplay between the two genes","volume":"159","author":"Lee","year":"2021","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122698","article-title":"microRNAs in Parkinson's disease: from pathogenesis to novel diagnostic and therapeutic approaches","volume":"18","author":"Leggio","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ncrna8010010","article-title":"A structural view of miRNA biogenesis and function","volume":"8","author":"Leit\u00e3o","year":"2022","journal-title":"Non-coding RNA"},{"issue":"R1","key":"10.1016\/j.neuropharm.2025.110542_bib98","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","article-title":"Parkinson's disease: from monogenic forms to genetic susceptibility factors","volume":"18","author":"Lesage","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib99","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s13577-017-0187-5","article-title":"MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3","volume":"31","author":"Li","year":"2018","journal-title":"Hum. Cell"},{"key":"10.1016\/j.neuropharm.2025.110542_bib100","article-title":"Targeting microglial \u03b1-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson's disease","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib101","article-title":"MicroRNAs play a role in Parkinson's disease by regulating microglia function: from pathogenetic involvement to therapeutic potential","volume":"14","author":"Li","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.744942","article-title":"MicroRNAs play a role in Parkinson's disease by regulating microglia function: from pathogenetic involvement to therapeutic potential","volume":"14","author":"Li","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12017-021-08676-w","article-title":"Diagnostic performance of miR-485-3p in patients with Parkinson's disease and its relationship with neuroinflammation","volume":"24","author":"Lin","year":"2022","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.neuropharm.2025.110542_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.591183","article-title":"Profiling non-motor symptoms in monogenic Parkinson's disease","volume":"12","author":"Liu","year":"2020","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib105","doi-asserted-by":"crossref","first-page":"bbaa324","DOI":"10.1093\/bib\/bbaa324","article-title":"A systematic analysis of miRNA markers and classification algorithms for forensic body fluid identification","volume":"22","author":"Liu","year":"2021","journal-title":"Briefings Bioinf."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110542_bib106","doi-asserted-by":"crossref","DOI":"10.32604\/biocell.2024.049130","article-title":"Pathogenic genes associated with Parkinson's disease: molecular mechanism overview","volume":"48","author":"Liu","year":"2024","journal-title":"Biocell"},{"key":"10.1016\/j.neuropharm.2025.110542_bib107","series-title":"Promises and Challenges of miRNA Therapeutics","first-page":"F673","author":"Long","year":"2022"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3892\/ijmm.2023.5253","article-title":"Autophagy-regulating miRNAs: novel therapeutic targets for Parkinson's disease","volume":"51","author":"Ma","year":"2023","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3892\/ijmm.2023.5253","article-title":"Autophagy-regulating miRNAs: novel therapeutic targets for Parkinson's disease","volume":"51","author":"Ma","year":"2023","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib110","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/jnnp.2004.046888","article-title":"Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease","volume":"76","author":"Madegowda","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110542_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175875","article-title":"Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease","volume":"954","author":"Mansour","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib112","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11064-017-2185-0","article-title":"The NLRP3 inflammasome is involved in the pathogenesis of Parkinson's disease in rats","volume":"42","author":"Mao","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2025.110542_bib113","article-title":"Retracted: inhibition of miR-421 preserves mitochondrial function and protects against Parkinson's disease pathogenesis via pink1\/parkin-dependent mitophagy","volume":"2023","author":"Markers","year":"2023","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib114","first-page":"1","article-title":"Unravelling cell type-specific responses to Parkinson's Disease at single cell resolution","volume":"19","author":"Martirosyan","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110542_bib115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-323-85555-6.00018-7","article-title":"LRRK2: genetic mechanisms vs genetic subtypes","volume":"193","author":"Mata","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.30574\/gscbps.2024.27.3.0222","article-title":"Advance and opportunities in nanoparticle drug delivery for central nervous system disorders: a review of current advances","volume":"27","author":"Mendake","year":"2024","journal-title":"GSC Biological and Pharmaceutical Sciences"},{"key":"10.1016\/j.neuropharm.2025.110542_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154690","article-title":"The potential role of miRNAs in the pathogenesis of adrenocortical carcinoma - a focus on signaling pathways interplay","author":"Midan","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110542_bib118","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/hmg\/ddr210","article-title":"MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b\/c which modulate mitochondrial function","volume":"20","author":"Mi\u00f1ones-Moyano","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155023","article-title":"Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Parkinson's disease","volume":"253","author":"Mohammed","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155023","article-title":"Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Parkinson's disease","volume":"253","author":"Mohammed","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116691","article-title":"Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders","volume":"175","author":"Naimi","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110542_bib122","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib123","series-title":"Seminars in Cell & Developmental Biology","article-title":"MicroRNAs in shaping the resolution phase of inflammation","author":"Naqvi","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110542_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.660379","article-title":"MicroRNA dysregulation in Parkinson's disease: a narrative review","volume":"15","author":"Nies","year":"2021","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib125","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1471-4159.2012.07809.x","article-title":"Leucine\u2010rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin\u2010like protein","volume":"122","author":"Niu","year":"2012","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib126","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s42003-021-02973-7","article-title":"Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease","volume":"5","author":"Novak","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib127","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fneur.2020.00527","article-title":"Association between glucocerebrosidase mutations and Parkinson's disease in Ireland","volume":"11","author":"Olszewska","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib128","first-page":"73","article-title":"MicroRNA-499 gene expression in Egyptian type 2 diabetes mellitus patients with and without coronary heart disease","volume":"2","author":"Oraby","year":"2022","journal-title":"Azhar Intern. J. Pharmaceut. Med. Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.genrep.2022.101712","article-title":"Association of miRNA-499 rs3746444 A>G genotype variants with type 2 diabetes mellitus and its coronary heart disease complication in adult Egyptian population","volume":"29","author":"Oraby","year":"2022","journal-title":"Gene Reports"},{"key":"10.1016\/j.neuropharm.2025.110542_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110542_bib131","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson's disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2025.110542_bib132","series-title":"MicroRNA in Human Infectious Diseases","first-page":"3","article-title":"Paradigms in miRNA biogenesis pathways","author":"Panda","year":"2024"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110542_bib133","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/brainsci13081146","article-title":"The genetic basis of probable REM sleep behavior disorder in Parkinson's disease","volume":"13","author":"Perez-Lloret","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/401264","article-title":"Oxidative stress and microglial cells in Parkinson's disease","volume":"2012","author":"Peterson","year":"2012","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib136","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s10020-021-00426-9","article-title":"Relationship between brain iron deposition and mitochondrial dysfunction in idiopathic Parkinson's disease","volume":"28","author":"Prasuhn","year":"2022","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib137","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/ijms22031176","article-title":"Measurements methods for the development of MicroRNA-based tests for cancer diagnosis","volume":"22","author":"Precazzini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.neuropharm.2025.110542_bib138","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.7150\/ijms.102123","article-title":"Decoding the promise and challenges of miRNA-based cancer therapies: an essential update on miR-21, miR-34, and miR-155","volume":"21","author":"Qian","year":"2024","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.31083\/j.jin2202045","article-title":"MiRNA-1976 regulates the apoptosis of dopaminergic neurons by targeting the PINK1 gene","volume":"22","author":"Qiu","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12868-015-0192-0","article-title":"Exogenous \u03b1-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes","volume":"16","author":"Rannikko","year":"2015","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib141","article-title":"Plasma expression and bioinformatic analysis of Mir-16, Mir-132, Mir-146 and Mir-223 in patients with rheumatoid arthritis","volume":"42","author":"Raslan","year":"2024","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib142","unstructured":"Ratterman, R.J., In memory of Richard J. Ratterman and Donald A. Rudler. 2021, Carnegie Mellon University."},{"key":"10.1016\/j.neuropharm.2025.110542_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102090","article-title":"The role of microRNAs in the pathophysiology of human central nervous system: a focus on neurodegenerative diseases","author":"Rezaee","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib144","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110542_bib145","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nchembio807","article-title":"The role of iron regulatory proteins in mammalian iron homeostasis and disease","volume":"2","author":"Rouault","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.4014","article-title":"Molecular insights into the potential effects of selective estrogen receptor \u03b2 agonists in Alzheimer's and Parkinson's diseases","volume":"42","author":"Rymbai","year":"2024","journal-title":"Cell Biochem. Funct."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib147","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1007\/s12035-024-04111-w","article-title":"Parkinson\u2019s disease and MicroRNAs: a duel between inhibition and stimulation of apoptosis in neuronal cells","volume":"61","author":"Saadh","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib148","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/14737175.2015.1114886","article-title":"MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases","volume":"22","author":"Saghazadeh","year":"2022","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010712","article-title":"Role and dysregulation of miRNA in patients with Parkinson's disease","volume":"24","author":"Salemi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib150","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/ijms24010712","article-title":"Role and dysregulation of miRNA in patients with Parkinson's disease","volume":"24","author":"Salemi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib151","article-title":"Biogenesis, characterization, and functions of mirtrons","volume":"13","author":"Salim","year":"2022","journal-title":"Wiley Interdisc. Rev.: RNA"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib152","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/humrep\/det422","article-title":"Dopamine in human follicular fluid is associated with cellular uptake and metabolism-dependent generation of reactive oxygen species in granulosa cells: implications for physiology and pathology","volume":"29","author":"Saller","year":"2013","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.neuropharm.2025.110542_bib153","article-title":"Genetics of Parkinson's disease: recessive forms","volume":"4","author":"Salles","year":"2024","journal-title":"Neurology Perspectives"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110542_bib154","doi-asserted-by":"crossref","first-page":"Fso829","DOI":"10.2144\/fsoa-2022-0074","article-title":"The expression profiling of serum miR-92a, miR-134 and miR-375 in acute ischemic stroke","volume":"8","author":"Salman","year":"2022","journal-title":"Future Sci OA"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib155","first-page":"66","article-title":"The clinical value of circulating microRNAs in acute ischemic stroke","volume":"2","author":"Salman","year":"2022","journal-title":"Azhar Intern. J. Pharmaceut. Med. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib156","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/cells10061410","article-title":"Regulatory miRNA\u2013mRNA networks in Parkinson's disease","volume":"10","author":"Santos-Lobato","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib157","doi-asserted-by":"crossref","DOI":"10.1080\/23262133.2016.1256855","article-title":"Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson's disease","volume":"3","author":"Saraiva","year":"2016","journal-title":"Neurogenesis"},{"key":"10.1016\/j.neuropharm.2025.110542_bib158","article-title":"Insights from single-cell RNA-seq: identifying the actin gene family as novel drivers in Parkinson's disease","author":"Sayad","year":"2024","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110542_bib159","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/mds.29821","article-title":"Autosomal dominant Parkinson\u2019s disease caused by SNCA p. E46K mutation in a family with Russian ancestry","volume":"39","author":"Senkevich","year":"2024","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib160","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib161","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11033-024-09520-7","article-title":"Interplay between \u03b1-synuclein and parkin genes: insights of Parkinson's disease","volume":"51","author":"Sharma","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1567","article-title":"miR\u201030b protects nigrostriatal dopaminergic neurons from MPP (+)\u2010induced neurotoxicity via SNCA","volume":"10","author":"Shen","year":"2020","journal-title":"Brain Behavior"},{"key":"10.1016\/j.neuropharm.2025.110542_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1385675","article-title":"Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson's disease","volume":"18","author":"Shi","year":"2024","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib164","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40478-024-01803-1","article-title":"Single-nucleus multi-omics of Parkinson's disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks","volume":"12","author":"Shwab","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2025.110542_bib165","first-page":"103","volume":"vol. 98","author":"Simpson","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110542_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.971252","article-title":"Genetic variations in GBA1 and LRRK2 genes: biochemical and clinical consequences in Parkinson disease","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib167","doi-asserted-by":"crossref","first-page":"930","DOI":"10.7150\/thno.7026","article-title":"MicroRNAs-the next generation therapeutic targets in human diseases","volume":"3","author":"Srinivasan","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.neuropharm.2025.110542_bib168","article-title":"Identification of significant differentially expressed miRNA and their targets common in idiopathic Parkinson's diseaseand Parkinson plus syndrome","volume":"39","author":"Srivastava","year":"2024","journal-title":"Hum. Genet."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib169","article-title":"Genetic variants in mRNA untranslated regions","volume":"9","author":"Steri","year":"2018","journal-title":"Wiley Interdisc. Rev.: RNA"},{"key":"10.1016\/j.neuropharm.2025.110542_bib170","series-title":"Parkinson's Disease: Neurophysiological, Clinical, and Related Aspects","first-page":"291","article-title":"Postmenopausal parkinsonism: brain iron overload?","author":"Still","year":"1977"},{"key":"10.1016\/j.neuropharm.2025.110542_bib171","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","article-title":"Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson's disease","volume":"373","author":"Stojkovska","year":"2018","journal-title":"Cell Tissue Res."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110542_bib172","doi-asserted-by":"crossref","first-page":"23379","DOI":"10.1002\/jcp.28907","article-title":"MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson's disease mouse model","volume":"234","author":"Sun","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib173","first-page":"206","article-title":"The role of the microRNA regulatory network in Alzheimer's disease: a bioinformatics analysis","volume":"18","author":"Sun","year":"2022","journal-title":"Arch. Med. Sci.: AMS"},{"key":"10.1016\/j.neuropharm.2025.110542_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.767064","article-title":"miR-21 in human cardiomyopathies","volume":"8","author":"Surina","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib175","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41598-024-54299-z","article-title":"Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson's disease patients","volume":"14","author":"Szatm\u00e1ri","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110542_bib176","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7759053","article-title":"A glance at biogenesis and functionality of MicroRNAs and their role in the neuropathogenesis of Parkinson's disease","volume":"2023","author":"Szel\u0105gowski","year":"2023","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2025.110542_bib177","article-title":"Is Gauchian genotyping of GBA1 variants reliable?","author":"Tayebi","year":"2023","journal-title":"medRxiv"},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110542_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413302","article-title":"Nanoparticle strategies for treating CNS disorders: a comprehensive review of drug delivery and theranostic applications","volume":"25","author":"Toader","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.668648","article-title":"The MicroRNA family gets wider: the IsomiRs classification and role","volume":"9","author":"Tomasello","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"Preprint","key":"10.1016\/j.neuropharm.2025.110542_bib181","first-page":"1","article-title":"Understanding the involvement of microRNAs in mitochondrial dysfunction and their role as potential biomarkers and therapeutic targets in Parkinson's disease","author":"Tryphena","year":"2022","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2025.110542_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111826","article-title":"Involvement of miRNA on epigenetics landscape of Parkinson's disease: from pathogenesis to therapeutics","volume":"213","author":"Uppala","year":"2023","journal-title":"Mech. Ageing Dev."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib183","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/mds.29939","article-title":"Small particles, big potential: polymeric nanoparticles for drug delivery in Parkinson's disease","volume":"39","author":"Virameteekul","year":"2024","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib184","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/humu.21248","article-title":"Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease","volume":"31","author":"Voutsinas","year":"2010","journal-title":"Hum. Mutat."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110542_bib185","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.3390\/ijms22115606","article-title":"Potential effects of leukotriene receptor antagonist montelukast in treatment of neuroinflammation in Parkinson's disease","volume":"22","author":"Wallin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110542_bib186","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/gtc.12764","article-title":"miR\u201029c\u20103p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease","volume":"25","author":"Wang","year":"2020","journal-title":"Genes Cells"},{"key":"10.1016\/j.neuropharm.2025.110542_bib187","article-title":"Single-cell transcriptomic atlas of the human substantia nigra in Parkinson's disease","author":"Wang","year":"2022","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib188","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12967-024-04881-w","article-title":"MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib189","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12967-024-04881-w","article-title":"MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib190","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41572-020-00223-4","article-title":"Delirium","volume":"6","author":"Wilson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110542_bib191","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.neurobiolaging.2013.09.027","article-title":"MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration","volume":"35","author":"Xiong","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110542_bib192","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1007\/s10571-023-01362-4","article-title":"Transcriptomics and proteomics approach for the identification of altered blood microRNAs and plasma proteins in Parkinson's disease","volume":"43","author":"Yadav","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110542_bib193","first-page":"1009","article-title":"Parkin, PINK1, DJ-1 and mitochondria dysfunction with Parkinson's disease","volume":"22","author":"Yang","year":"2010","journal-title":"Chin. Bull. Life Sci."},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110542_bib194","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1093\/hmg\/ddz080","article-title":"The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease","volume":"28","author":"Yi","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2025.110542_bib195","first-page":"2022","article-title":"Identification of potential miRNA-mRNA regulatory network contributing to Parkinson's disease","author":"Yin","year":"2021","journal-title":"Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib196","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib197","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2017.10.368","article-title":"Autophagy functions of genes mutated in ALS and Parkinson's disease","volume":"112","author":"Youle","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib198","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41597-024-03909-6","article-title":"Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson's disease patients","volume":"11","author":"Yu","year":"2024","journal-title":"Sci. Data"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110542_bib199","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41531-025-00914-3","article-title":"Deciphering shared molecular dysregulation across Parkinson's disease variants using a multi-modal network-based data integration and analysis","volume":"11","author":"Zagare","year":"2025","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2025.110542_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154437","article-title":"The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy","author":"Zaki","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2025.110542_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2024.137792","article-title":"Unraveling the regulatory landscape of Parkinson disease: a molecular symphony of miRNAs, transcription factors, and high-risk genes","volume":"832","author":"Zameer","year":"2024","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110542_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1134\/S106816202001015X","article-title":"The fundamentals of miRNA biology: structure, biogenesis, and regulatory functions","volume":"46","author":"Zaporozhchenko","year":"2020","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2025.110542_bib203","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fnagi.2015.00248","article-title":"Parkin regulation and neurodegenerative disorders","volume":"7","author":"Zhang","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","article-title":"Integrated genetic analysis of racial differences of common GBA variants in Parkinson's disease: a meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110542_bib205","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s13311-021-01130-6","article-title":"MicroRNA-7 protects against neurodegeneration induced by \u03b1-synuclein preformed fibrils in the mouse brain","volume":"18","author":"Zhang","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110542_bib206","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1080\/21655979.2022.2033409","article-title":"LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p\/alpha-synuclein axis in Parkinson's disease","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.neuropharm.2025.110542_bib207","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1080\/21655979.2022.2033409","article-title":"LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p\/alpha-synuclein axis in Parkinson's disease","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.neuropharm.2025.110542_bib208","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2024.04.002","article-title":"Targeting NKA\u03b11 to treat Parkinson's disease through inhibition of mitophagy-dependent ferroptosis","volume":"218","author":"Zhang","year":"2024","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110542_bib209","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nrl.2022.03.002","article-title":"Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson's disease: a meta-analysis","volume":"39","author":"Zhang","year":"2024","journal-title":"Neurologia"},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110542_bib210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037470","article-title":"Identification of serum microRNA alterations associated with long-term exercise-induced motor improvements in patients with Parkinson disease","volume":"103","author":"Zhang","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.neuropharm.2025.110542_bib211","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neulet.2017.10.051","article-title":"Hsp70 participates in PINK1-mediated mitophagy by regulating the stability of PINK1","volume":"662","author":"Zheng","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110542_bib212","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.851135","article-title":"Glucocerebrosidase mutations cause mitochondrial and lysosomal dysfunction in Parkinson's disease: pathogenesis and therapeutic implications","volume":"14","author":"Zheng","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110542_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease","volume":"11","author":"Zhou","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110542_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105197","article-title":"miR-103a-3p regulates mitophagy in Parkinson's disease through Parkin\/Ambra1 signaling","volume":"160","author":"Zhou","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"771","key":"10.1016\/j.neuropharm.2025.110542_bib215","doi-asserted-by":"crossref","first-page":"eabo1997","DOI":"10.1126\/scitranslmed.abo1997","article-title":"Single-cell transcriptomic and proteomic analysis of Parkinson's disease Brains","volume":"16","author":"Zhu","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2025.110542_bib216","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease","volume":"155","author":"Zucca","year":"2017","journal-title":"Prog. Neurobiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:24:05Z","timestamp":1779614645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":216,"alternative-id":["S0028390825002485"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110542","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking molecular secrets: The role of miRNAs in Parkinson's disease dynamics","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110542"}}